Strategic asset sale Recent asset divestiture to Spoke Sciences includes a patent portfolio on SNAC with non-water-soluble lipophilic actives, presenting an opportunity for partner-backed licensing or co-development of delivery-enhanced formulations.

Cannabinoid delivery focus Specialization in oral and inhaled delivery technologies for CNS and cannabinoid medicines positions the company to engage with pharma players seeking validated delivery platforms to improve bioavailability and patient outcomes.

Early-stage revenue With revenue in the low single-digit millions and a substantial funding runway, there is room for BD leverage toward strategic collaborations, joint ventures, or milestone-rich partnerships to scale commercialization.

Patent-backed potential Patented product candidates targeting anxiety and agitation in autism and related CNS indications offer a clear route for licensing discussions, especially with companies seeking niche CNS assets.

Strategic financing Existing funding of around the mid-tens of millions provides a platform for co-development or sponsored research arrangements with larger pharma partners to accelerate clinical and regulatory timelines.